Global pharmaceutical giants are turbocharging their investments in Chinese drugmakers, eager to seize the explosive growth of the country’s biotech sector and tap into its enormous market potential. This bold strategic move is transforming the industry landscape like never before
China is boldly challenging the U.S.’ leadership in pharmaceutical manufacturing as the Trump administration shakes up research policies. This dramatic shift sparks worries about America’s future grip on drug-making supremacy
Canada is set to emerge as a key contender in the global race to produce generic versions of Ozempic, the popular diabetes medication, as manufacturers prepare for accelerated approvals and exciting new market opportunities on the horizon
Charted: U.S. pharmaceutical drug imports from China highlight a growing dependence on vital raw materials and finished products. Visual Capitalist’s latest data uncovers the powerful trends reshaping the supply chain and transforming the market landscape
